Profund Advisors LLC Has $657,000 Stock Holdings in Vericel Co. (NASDAQ:VCEL)

Profund Advisors LLC lowered its stake in Vericel Co. (NASDAQ:VCEL) by 50.4% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 14,311 shares of the biotechnology company’s stock after selling 14,534 shares during the period. Profund Advisors LLC’s holdings in Vericel were worth $657,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. MCF Advisors LLC grew its position in shares of Vericel by 86.1% in the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 223 shares during the last quarter. CWM LLC grew its holdings in Vericel by 319.0% in the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 504 shares in the last quarter. Nisa Investment Advisors LLC increased its position in Vericel by 9.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after buying an additional 220 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Vericel by 178.7% during the first quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock worth $134,000 after buying an additional 1,657 shares in the last quarter. Finally, RiverPark Advisors LLC bought a new stake in shares of Vericel in the first quarter valued at about $147,000.

Vericel Stock Performance

Vericel stock opened at $44.74 on Wednesday. The stock has a fifty day moving average of $48.07 and a 200-day moving average of $47.44. The stock has a market capitalization of $2.17 billion, a P/E ratio of -4,474.00 and a beta of 1.67. Vericel Co. has a 52 week low of $30.18 and a 52 week high of $54.10.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). Vericel had a return on equity of 0.35% and a net margin of 0.37%. The firm had revenue of $52.70 million during the quarter, compared to the consensus estimate of $52.59 million. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. The business’s quarterly revenue was up 14.8% on a year-over-year basis. On average, research analysts forecast that Vericel Co. will post 0.12 earnings per share for the current year.

Insider Buying and Selling at Vericel

In other news, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of the stock in a transaction on Friday, July 12th. The stock was sold at an average price of $50.00, for a total value of $250,000.00. Following the completion of the transaction, the chief financial officer now directly owns 14,436 shares in the company, valued at approximately $721,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Vericel news, insider Sean C. Flynn sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $52.18, for a total transaction of $782,700.00. Following the sale, the insider now directly owns 707 shares of the company’s stock, valued at approximately $36,891.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of the stock in a transaction on Friday, July 12th. The shares were sold at an average price of $50.00, for a total value of $250,000.00. Following the completion of the sale, the chief financial officer now owns 14,436 shares of the company’s stock, valued at $721,800. The disclosure for this sale can be found here. Insiders have sold 38,045 shares of company stock worth $1,956,725 over the last quarter. Corporate insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

VCEL has been the subject of several analyst reports. TD Cowen lifted their price objective on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. HC Wainwright raised their target price on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Truist Financial boosted their price target on Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. StockNews.com lowered Vericel from a “hold” rating to a “sell” rating in a research note on Friday, September 20th. Finally, Stephens lifted their price objective on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.75.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.